SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-002104
Filing Date
2023-02-27
Accepted
2023-02-27 06:48:38
Documents
15
Period of Report
2023-02-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20230227x8k.htm   iXBRL 8-K 44814
2 EX-1.1 plx-20230227xex1d1.htm EX-1.1 277268
3 EX-5.1 plx-20230227xex5d1.htm EX-5.1 17405
4 GRAPHIC plx-20230227xex5d1002.jpg GRAPHIC 8208
  Complete submission text file 0001558370-23-002104.txt   534524

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20230227.xsd EX-101.SCH 3257
6 EX-101.LAB plx-20230227_lab.xml EX-101.LAB 16018
7 EX-101.PRE plx-20230227_pre.xml EX-101.PRE 10763
9 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230227x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 23669989
SIC: 2836 Biological Products, (No Diagnostic Substances)